Positron emission tomography of brain β-amyloid and tau levels in adults with down syndrome

Archives of Neurology

Volumn 68, Issue 6, 2011, Pages 768-774

  Nelson, Linda D ^a,c   Siddarth, Prabha ^a,c   Kepe, Vladimir ^a,b   Scheibel, Kevin E ^b   Huang, S C ^b   Barrio, Jorge R ^b   Small, Gary W ^a,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 [1 [6 [(2 FLUOROETHYL)METHYLAMINO] 2 NAPTHYL]ETHYLIDENE]MALONONITRILE F 18; AMYLOID BETA PROTEIN; CONTRAST MEDIUM; FLUORODEOXYGLUCOSE F 18; TAU PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGE DISTRIBUTION; AGED; ALZHEIMER DISEASE; ARTICLE; BEHAVIOR; BEHAVIOR DISORDER; BRAIN LEVEL; BRAIN REGION; CLINICAL ARTICLE; COGNITION; CONTROLLED STUDY; DOWN SYNDROME; FEMALE; HUMAN; IMAGE ANALYSIS; MALE; MIDDLE TEMPORAL GYRUS; NEUROPATHOLOGY; NEUROPSYCHOLOGICAL TEST; PARIETAL LOBE; POSITRON EMISSION TOMOGRAPHY; POSTERIOR CINGULATE; PRIORITY JOURNAL;

ADULT; AGED; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; CROSS-SECTIONAL STUDIES; DOWN SYNDROME; FEMALE; HUMANS; MALE; MIDDLE AGED; PLAQUE, AMYLOID; POSITRON-EMISSION TOMOGRAPHY; PROTEIN BINDING; TAU PROTEINS; YOUNG ADULT;

EID: 79958729432     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/archneurol.2011.104     Document Type: Article

References (55)

1. Margallo-Lana ML, Moore PB, Kay DW, et al. Fifteen-year follow-up of 92 hospitalized adults with Down's syndrome: incidence of cognitive decline, its relationship to age and neuropathology. J Intellect Disabil Res. 2007;51(pt 6):463-477. (Pubitemid 46746073)
2. Mann DM. The pathological association between Down syndrome and Alzheimer disease. Mech Ageing Dev. 1988;43(2):99-136.
3. Wisniewski KE, Dalton AJ, McLachlan C, Wen GY, Wisniewski HM. Alzheimer's disease in Down's syndrome: clinicopathologic studies. Neurology. 1985;35(7):957-961. (Pubitemid 15026265)
4. Hof PR, Bouras C, Perl DP, Sparks DL, Mehta N, Morrison JH. Age-related distribution of neuropathologic changes in the cerebral cortex of patients with Down's syndrome: quantitative regional analysis and comparison with Alzheimer's disease. Arch Neurol. 1995;52(4):379-391.
5. Mann DM, Esiri MM. The pattern of acquisition of plaques and tangles in the brains of patients under 50 years of age with Down's syndrome. J Neurol Sci. 1989;89(2-3):169-179. (Pubitemid 19052948)
6. Wisniewski KE, Wisniewski HM,Wen GY. Occurrence of neuropathological changes and dementia of Alzheimer's disease in Down's syndrome. Ann Neurol. 1985;17(3):278-282. (Pubitemid 15136603)
7. Mann DM, Yates PO, Marcyniuk B. Alzheimer's presenile dementia, senile dementia of Alzheimer type and Down's syndrome in middle age form an age related continuum of pathological changes. Neuropathol Appl Neurobiol. 1984; 10(3):185-207.
8. Mann DM, Yates PO, Marcyniuk B. Dopaminergic neurotransmitter systems in Alzheimer's disease and in Down's syndrome at middle age. J Neurol Neurosurg Psychiatry. 1987;50(3):341-344. (Pubitemid 17025876)
9. Armstrong RA. Differences in β-amyloid (β/A4) deposition in human patients with Down's syndrome and sporadic Alzheimer's disease. Neurosci Lett. 1994; 169(1-2):133-136.
10. Vetrivel KS, Thinakaran G. Amyloidogenic processing of β-amyloid precursor protein in intracellular compartments. Neurology. 2006;66(2)(suppl 1):S69-S73. (Pubitemid 43739988)
11. Leverenz JB, Raskind MA. Early amyloid deposition in the medial temporal lobe of young Down syndrome patients: a regional quantitative analysis. Exp Neurol. 1998;150(2):296-304. (Pubitemid 28231961)
12. Prasher VP, Filer A. Behavioural disturbance in people with Down's syndrome and dementia. J Intellect Disabil Res. 1995;39(pt 5):432-436.
13. Small GW, Kepe V, Ercoli LM, et al. PET of brain amyloid and tau in mild cognitive impairment. N Engl J Med. 2006;355(25):2652-2663. (Pubitemid 44969124)
14. Shoghi-Jadid K, Small GW, Agdeppa ED, et al. Localization of neurofibrillary tangles and β-amyloid plaques in the brains of living patients with Alzheimer disease. Am J Geriatr Psychiatry. 2002;10(1):24-35. (Pubitemid 34052900)
15. Smid LM, Vovko TD, Popovic M, et al. The 2,6-disubstituted naphthalene derivative FDDNP labeling reliably predicts Congo red birefringence of protein deposits in brain sections of selected human neurodegenerative diseases. Brain Pathol. 2006;16(2):124-130. (Pubitemid 43876472)
16. Boxer AL, Rabinovici GD, Kepe V, et al. Amyloid imaging in distinguishing atypical prion disease from Alzheimer disease. Neurology. 2007;69(3):283-290. (Pubitemid 47205691)
17. Small GW, Siddarth P, Burggren AC, et al. Influence of cognitive status, age, and APOE-4 genetic risk on brain FDDNP positron-emission tomography imaging in persons without dementia. Arch Gen Psychiatry. 2009;66(1):81-87.
18. Braskie MN, Klunder AD, Hayashi KM, et al. Plaque and tangle imaging and cognition in normal aging and Alzheimer's disease. Neurobiol Aging. 2010;31(10):1669-1678.
19. Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol. 2004;55(3):306-319. (Pubitemid 38269583)
20. Kepe V, Huang SC, Small GW, Satyamurthy N, Barrio JR. Visualizing pathology deposits in the living brain of patients with Alzheimer's disease. Methods Enzymol. 2006;412:144-160. (Pubitemid 44548579)
21. 18F] fluoroethyl) (methyl)amino]-2-naphthyl}ethylidene)malononitrile. Neuroscience. 2003;117 (3):723-730.
22. Folstein MF, Folstein SE, McHugh PR. "Mini-Mental State": a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189-198.
23. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. ed 4, text revision. Washington, DC: American Psychiatric Association; 2000.
24. Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med. 2004;256(3):183-194. (Pubitemid 39222988)
25. Winblad B, Palmer K, Kivipelto M, et al. Mild cognitive impairment - beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. J Intern Med. 2004;256(3):240-246. (Pubitemid 39222993)
26. Psychological Corporation. Wechsler Abbreviated Scale of Intelligence. San Antonio, TX: Harcourt Brace & Co; 1999.
27. Evenhuis HM. Evaluation of a screening instrument for dementia in ageing mentally retarded persons. J Intellect Disabil Res. 1992;36(pt 4):337-347.
28. Evenhuis HM. Manual of the Dementia Questionnaire 5 for Persons With Mental Retardation. 2nd ed. Zwammerdam, the Netherlands: Hooge Burch Institute for Mentally Retarded People; 1995.
29. Nelson L, Johnson JK, Freedman M, et al. Learning and memory as a function of age in Down syndrome: a study using animal-based tasks. Prog Neuropsychopharmacol Biol Psychiatry. 2005;29(3):443-453. (Pubitemid 40417596)
30. Kirk LJ, Hick R, Laraway A. Assessing dementia in people with learning disabilities: the relationship between two screening measures. J Intellect Disabil. 2006;10(4):357-364. (Pubitemid 44741880)
31. Prasher VP, Huxley A, Haque MS; Down Syndrome Ageing Study Group. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Down syndrome and Alzheimer's disease - pilot study. Int J Geriatr Psychiatry. 2002;17(3):270-278. (Pubitemid 34232600)
32. Coppus A, Evenhuis H, Verberne G-J, et al. Dementia and mortality in persons with Down's syndrome. J Intellect Disabil Res. 2006;50(pt 10):768-777. (Pubitemid 44336413)
33. Tyrrell J, Cosgrave M, McCarron M, et al. Dementia in people with Down's syndrome. Int J Geriatr Psychiatry. 2001;16(12):1168-1174. (Pubitemid 34044185)
34. Shultz J, Aman M, Kelbley T, et al. Evaluation of screening tools for dementia in older adults with mental retardation. Am J Ment Retard. 2004;109(2):98-110.
35. Nelson LD, Satz P, Mitrushina M, et al. Development and validation of the neuropsychology behavior and affect profile. Psychol Assess. 1989;1(4):266-272.
36. Nelson LD, Cichetti D, Satz P, Sowa M, Mitrushina M. Emotional sequelae of stroke: a longitudinal perspective. J Clin Exp Neuropsychol. 1994;16(5):796-806. (Pubitemid 24331919)
37. Nelson LD, Mitrushina M, Satz P, SowaM, Cohen S. Cross-validation of the Neuropsychology Behavior and Affect Profile in stroke patients. Psychol Assess. 1993;5(3):374-376.
38. Nelson LD, Scheibel KE, Ringman JM, Sayre JW. An experimental approach to detecting dementia in Down syndrome: a paradigm for Alzheimer's disease. Brain Cogn. 2007;64(1):92-103. (Pubitemid 46805116)
39. 18F]FDDNP) ready for animal or human administration. Mol Imaging Biol. 2007;9(1):6-16.
40. 18F-FDDNP scans. J Nucl Med. 2010;51(2):210-218.
41. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82(4):239-259.
42. Petersen RC, Parisi JE, Dickson DW, et al. Neuropathologic features of amnestic mild cognitive impairment. Arch Neurol. 2006;63(5):665-672.
43. Deb S, Braganza J. Comparison of rating scales for the diagnosis of dementia in adults with Down's syndrome. J Intellect Disabil Res. 1999;43(pt 5):400-407. (Pubitemid 29495566)
44. Burt DB, Primeaux-Hart S, Loveland KA, et al. Comparing dementia diagnostic methods used with people with intellectual disabilities. J Policy Pract Intell Disabil. 2005;2(2):94-115.
45. Ball SL, Holland AJ, Huppert FA, Treppner P, Watson P, Hon J. The modified CAMDEX informant interview is a valid and reliable tool for use in the diagnosis of dementia in adults with Down's syndrome. J Intellect Disabil Res. 2004;48(pt 6):611-620. (Pubitemid 39214380)
46. Adolphs R. Neural systems for recognizing emotion. Curr Opin Neurobiol. 2002;12(2):169-177. (Pubitemid 34518336)
47. Iacoboni M, Dapretto M. The mirror neuron system and the consequences of its dysfunction. Nat Rev Neurosci. 2006;7(12):942-951.
48. Schulte-Rüther M, Markowitsch HJ, Fink GR, Piefke M. Mirror neuron and theory of mind mechanisms involved in face-to-face interactions: a functional magnetic resonance imaging approach to empathy. J Cogn Neurosci. 2007;19(8):1354-1372. (Pubitemid 47204076)
49. Davidson RJ, Abercrombie H, Nitschke JB, Putnam K. Regional brain function, emotion and disorders of emotion. Curr Opin Neurobiol. 1999;9(2):228-234. (Pubitemid 29201797)
50. Nieuwenhuis-Mark RE. Diagnosing Alzheimer's dementia in Down syndrome: problems and possible solutions. Res Dev Disabil. 2009;30(5):827-838.
51. Schapiro MB, Haxby JV, Grady CL, et al. Decline in cerebral glucose utilisation and cognitive function with aging in Down's syndrome. J Neurol Neurosurg Psychiatry. 1987;50(6):766-774. (Pubitemid 17076292)
52. Schapiro MB, Haxby JV, Grady CL. Nature of mental retardation and dementia in Down syndrome: study with PET, CT, and neuropsychology. Neurobiol Aging. 1992;13(6):723-734.
53. Protas HD, Huang S-C, Kepe V, et al. FDDNP binding using MR derived cortical surface maps. Neuroimage. 2010;49(1):240-248.
54. 11C]PIB uptake shows predominantly striatal increase in variant Alzheimer's disease. Brain. 2008;131(pt 7):1845-1853.
55. Villemagne VL, Ataka S, Mizuno T, et al. High striatal amyloid beta-peptide deposition across different autosomal Alzheimer disease mutation types. Arch Neurol. 2009;66(12):1537-1544.